The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial.
 
Shuqiang Yuan
No Relationships to Disclose
 
Run-Cong Nie
No Relationships to Disclose
 
Ying Jin
No Relationships to Disclose
 
Cheng-cai Liang
No Relationships to Disclose
 
Rui Jian
No Relationships to Disclose
 
Yuan-fang Li
No Relationships to Disclose
 
Haibo Qiu
No Relationships to Disclose
 
Wei Wang
No Relationships to Disclose
 
Shi Chen
No Relationships to Disclose
 
Dong-sheng Zhang
No Relationships to Disclose
 
Chun-yu Huang
No Relationships to Disclose
 
Yi-hong Ling
No Relationships to Disclose
 
Qiu-xia Yang
No Relationships to Disclose
 
Zi-Xian Wang
No Relationships to Disclose
 
Wen-long Guan
No Relationships to Disclose
 
Ying-bo Chen
No Relationships to Disclose
 
Xiao-wei Sun
No Relationships to Disclose
 
Zhi-wei Zhou
No Relationships to Disclose
 
Feng Wang
No Relationships to Disclose
 
Rui-Hua Xu
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; Bristol-Myers Squibb; HenRui; Junshi Biosciences; KYM Biosciences; Merck Serono; Roche